(Q51036254)

27 March 2018

title

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. (English)

1 reference

27 March 2018

inflammatory bowel diseases

main subject

patient

0 references

1 reference

6

1 reference

27 March 2018

author name string

C Steenholdt

1

1 reference

27 March 2018

M Svenson

2

1 reference

27 March 2018

K Bendtzen

3

1 reference

27 March 2018

O Ø Thomsen

4

1 reference

27 March 2018

J Brynskov

5

1 reference

27 March 2018

language of work or name

English

0 references

publication date

3 May 2011

1 reference

27 March 2018

Alimentary Pharmacology & Therapeutics

published in

1 reference

27 March 2018

volume

34

1 reference

27 March 2018

issue

1

1 reference

27 March 2018

page(s)

51-58

1 reference

27 March 2018

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Serum sickness, encephalitis and other complications of anti-cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Acute infusion reactions induced by monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04682.X

10.1111/J.1365-2036.2011.04682.X

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

21535447

1 reference

27 March 2018